Benzinga Webinar: Pharma Companies vs. Tough Macro Backdrops

As we look forward to 2024, delivering for patients and investors will happen against a backdrop of the election, burgeoning AI, talent shortages, rising capital costs, challenging foreign exchange impacts, pressures on consumer spending, sticky inflation and ongoing regulatory scrutiny of transactions. These headwinds come on top of blockbuster patent expiries, rising competition across most therapeutic areas and the impact of the Inflation Reduction Act (IRA) of 2022. ----------------------------------------------------------------------------------------------------------------------------------------------------------- Opening Remarks Matt Steinmetz, VP, Virtual Events - Benzinga Fireside Gaurav Shah, CEO - Rocket Pharmaceuticals (NASDAQ: RCKT) Tony Noto, Editor - Benzinga Fireside Marc Hertz, Co-Founder & CEO - GRI Bio (NASDAQ: GRI) Tony Noto, Editor - Benzinga Fireside Chirinjeev Kathuria, Founder & Chairman - Ocean Biomedical (NASDAQ: OCEA) Tony Noto, Editor - Benzinga Fireside John Climaco, Chairman & CEO - CNS Pharmaceuticals (NASDAQ: CNSP) Aaron Bry, Reporter - Benzinga Fireside Andreas Argyrides, Biotech Equity Research Analyst - Wedbush Securities Tony Noto, Editor - Benzinga Fireside Danny Yeung, Co-founder & CEO - Prenetics Global (NASDAQ: PRE) Tony Noto, Editor - Benzinga Fireside Len Liptak, CEO - ProSomnus (NASDAQ: OSA) Tony Noto, Editor - Benzinga Fireside Thomas Sandgaard, President & CEO - Zynex (NASDAQ: ZYXI) Aaron Bry, Reporter - Benzinga Closing Remarks Matt Steinmetz, VP, Virtual Events - Benzinga ----------------------------------------------------------------------------------------------------------------------------------------------------------- Check out www.benzinga.com for complete coverage along with all the latest financial news and data! Follow us Online! 📸Instagram: www.instagram.com/benzinga 👍Facebook: www.facebook.com/Benzinga 📱TikTok: www.tiktok.com/@benzinga 🐤Twitter: twitter.com/Benzinga Disclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions. #Benzinga #BioTech #Webinar